Nancy Lin
机构: Dana-Farber Cancer Institute
每年引用次数
引用次数
引用: 37,044
H-指数: 91
I10-指数 : 262
出版物: 726
Abstract GS2-02: Acquired activating mutations in RTKs confer endocrine resistance in ER+ metastatic breast cancer through ER-reprogramming, MAPK signaling, and an induced stem-like cell state
Ofir Cohen , Pingping Mao , Utthara Nayar , Jorge E Buendia-Bue
Cancer Research 80
2020
The Neurologic Assessment in Neuro-Oncology (NANO) Scale: A Tool to Assess Neurologic Function for Integration in the Radiologic Assessment in Neuro-Oncology (RANO) Criteria (S22.005)
David Peereboom , Kurt Jaeckle , Lisa DeAngelis , David Reardon
Neurology 82
7
2014
Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder)
Funda Meric-Bernstam , Kathy S Albain , Suzette Delaloge , Gabriel Hortobagyi
Cancer Research 81
48
2021
Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer
Patrick G. Morris , Neil M. Iyengar , Sujata Patil , Carol Chen
Cancer 119 ( 22) 3943 -3951
15
2013
Abstract GS1-01: Tucatinib vs placebo, both combined with capecitabine and trastuzumab, for patients with pretreated HER2-positive metastatic breast cancer with and without brain metastases (HER2CLIMB)
Rashmi Murthy , Sherene Loi , Alicia Okines , Elisavet Paplomata
Cancer Research 80
2
2020
Abstract GS6-05: A joint atlas of single-cell and bulk RNA-seq in metastatic breast cancer allows inference of oncogenic and drug-resistant transcriptional programs in malignant cells and the tumor microenvironment
Ofir Cohen , Daniel Abravanel , Michal Slyper , Johanna Klughammer
Cancer Research 80
2020
Abstract P3-01-09: Clonal heterogeneity and tumor evolution inform treatment resistance in a patient with HER2+ breast cancer
Jorge E. Buendia-Buendia , Sonia Pernas , Ofir Cohen , Ping Ping Mao
Cancer Research
2020
Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
Chau Dang , Nancy Lin , Beverly Moy , Steven Come
Journal of Clinical Oncology 28 ( 18) 2982 -2988
39
2010
In Regard to Yamamoto et al
Paul W. Sperduto , Penny K. Sneed , David Roberge , Ryan Shanley
International Journal of Radiation Oncology Biology Physics 84 ( 4) 875 -876
3
2012
Ethics of Mandatory Research Biopsy for Correlative End Points Within Clinical Trials in Oncology
Jeffrey Peppercorn , Iuliana Shapira , Deborah Collyar , Teresa Deshields
Journal of Clinical Oncology 28 ( 15) 2635 -2640
66
2010
Vitamin D Receptor Polymorphisms, Bone Mineral Density, and Bone Metabolism in Postmenopausal Mexican–American Women
Laurel McClure , T. Ross Eccleshall , Coleman Gross , Marie Luz Villa
Journal of Bone and Mineral Research 12 ( 2) 234 -240
63
1997
Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).
Patrick Glyn Morris , Neil M. Iyengar , Sujata Patil , Carol Chen
Journal of Clinical Oncology 31 167 -167
1
2013
Reply to M.C. Chamberlain et al
Paul W. Sperduto , Norbert Kased , David Roberge , Zhiyuan Xu
Journal of Clinical Oncology 30 ( 26) 3316 -3317
2012
CMET-22. INTRATHECAL (IT) TRAZTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE (HER2+) CANCER: A MULTICENTER PHASE 1/2 STUDY
Priya Kumthekar , William Gradishar , Nancy Lin , Elena Pentsova
Neuro-oncology 20
6
2018
CMET-20. EVIDENCE OF CNS RESPONSE OF PEMBROLIZUMAB FOR LEPTOMENINGEAL CARCINOMATOSIS AT A SINGLE CELL RESOLUTION
Ivanna Bihun , Ugonma Chukwueke , Kevin Oh , Michael White
Neuro-oncology 20
2018
NIMG-63. ADVANCED IMAGING FOR ASSESSING VOLUMETRIC RESPONSES IN BRAIN METASTASES TREATED WITH CHECKPOINT BLOCKADE
Elizabeth Gerstner , Jonathan Cardona , Ken Chang , Andrew Beers
Neuro-oncology 20
2018
Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications.
Adrienne Boire , Dieta Brandsma , Priscilla K Brastianos , Emilie Le Rhun
Neuro-oncology 21 ( 5) 571 -583
99
2019
INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS
Eudocia Lee , Ugonma Chukwueke , Shawn Hervey-Jumper , John DeGroot
Neuro-oncology 21
3
2019
CTNI-02. TBCRC049: A PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE COMBINATION OF TUCATINIB, TRASTUZUMAB AND CAPECITABINE FOR THE TREATMENT OF LEPTOMENINGEAL METASTASIS IN HER2 POSITIVE BR1AST CANCER
Rashmi Murthy , Barbara O’Brien , Donald Berry , Nicholas Navin
Neuro-oncology 22
2020
NIMG-05. ADVANCED IMAGING TO ASSESS LONGITUDINAL VASCULAR CHANGES IN BRAIN METASTASES TREATED WITH CHECKPOINT INHIBITION
Albert Kim , Jonathan Cardona , Ken Chang , Andrew Beers
Neuro-oncology 22
2020